Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases.
Scholar Rock is discovering and developing a new class of biologic therapies to selectively target dysregulated growth factors in the disease microenvironment by modulating supracellular activation, resulting in therapeutic effects specifically at the source of disease.
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies.
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases.